Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Hans-Friedrich Koch"'
Autor:
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller
Publikováno v:
Breast, Vol 58, Iss , Pp 18-26 (2021)
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast c
Externí odkaz:
https://doaj.org/article/398ce9856ea34116bdedd35208f23846
Autor:
Cornelius F. Waller, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Eduardo Yanez Ruiz, Ihor Vynnychenko, Unmesh Gopalakrishnan, Abhijit Barve, Jay Herson, Ashwani Marwah, Virote Sriuranpong, Sirshendu Roy, Hope S. Rugo, Alexey Manikhas, Miguel Hernandez-Bronchud, Subramanian Loganathan, Hans Friedrich Koch, Joseph D. Parra, Sarika Deodhar, Igor Bondarenko, Eduardo J. Pennella
Publikováno v:
Breast, Vol 58, Iss, Pp 18-26 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Background Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast ca
Autor:
Alexey Manikhas, Hans Friedrich Koch, Charuwan Akewanlop, Kakhaber Baramidze, Sirshendu Roy, Gopichand Mamillapalli, Ashwani Marwah, Virote Sriuranpong, Eduardo Yanez Ruiz, Miguel Hernandez-Bronchud, Unmesh Gopalakrishnan, Maria Luisa T. Abesamis-Tiambeng, Guzel Mukhametshina, Abhijit Barve, Joseph D. Parra, Adolfo Fuentes-Alburo, Ihor Vynnychenko, Sarika Deodhar, Gia Nemsadze, Igor Bondarenko, Eduardo J. Pennella, Cornelius F. Waller, Hope S. Rugo, Jay Herson, Subramanian Loganathan
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, vol 188, iss 2
Breast cancer research and treatment, vol 188, iss 2
Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined w
Autor:
Nikos Emmanouilidis, Julius Boeckler, Bastian P. Ringe, Alexander Kaltenborn, Frank Lehner, Hans Friedrich Koch, Jürgen Klempnauer, Harald Schrem
Publikováno v:
Journal of Transplantation, Vol 2017 (2017)
Background. This retrospective cohort study evaluates the advantages of risk balancing between prolonged cold ischemic time (CIT) and late night surgery. Methods. 1262 deceased donor kidney transplantations were analyzed. Multivariable regression was
Externí odkaz:
https://doaj.org/article/2c1f37dd4e754714ab4e2feeade782e4
Autor:
Jill Gwiasda, Sebastian Liersch, Jürgen Klempnauer, Harald Schrem, Soufiane Filali Bouami, Eduardo M. Suero, Christian Krauth, Jan Beneke, Alexander Kaltenborn, Hans-Friedrich Koch
Publikováno v:
Langenbeck's Archives of Surgery. 403:495-508
Prognostic factors for survival ≥ 15 years and life years lost after liver transplantation are largely unknown. One thousand six hundred thirty primary adult liver transplants between 1983 and 2014 were analyzed. Risk factors for survival were iden
Autor:
Jill Gwiasda, Daniel Pöhnert, Hans-Friedrich Koch, Alexander Kaltenborn, Harald Schrem, Sophia Volz, Markus Winny, Jürgen Klempnauer, Alon Goldis, Priscila Kürsch
Publikováno v:
Langenbeck's Archives of Surgery. 403:61-71
This study investigated the utility of retrospective two one-sided cumulative sum (CUSUM) charts combined with multivariable regression analysis in liver transplantation for transplant center benchmarking. One thousand seven hundred and forty-nine co
Autor:
Harald Schrem, Nikos Emmanouilidis, Jürgen Klempnauer, Frank Lehner, Julius Boeckler, Hans Friedrich Koch, Alexander Kaltenborn, Bastian P. Ringe
Publikováno v:
Journal of Transplantation, Vol 2017 (2017)
Journal of Transplantation
Journal of Transplantation
Background.This retrospective cohort study evaluates the advantages of risk balancing between prolonged cold ischemic time (CIT) and late night surgery.Methods.1262 deceased donor kidney transplantations were analyzed. Multivariable regression was us
Autor:
Anna Lochocka, Mario Berli, Cesar Gonzalo Calvo Vargas, Christelle Foucher, Petr Reichert, Axel Schaeffer, Hans-Friedrich Koch, Patrick Aubonnet, Dmitry Belenky
Publikováno v:
Cardiovascular Therapeutics. 33:329-337
SummaryAims Guidelines propose additional therapy to statin to treat elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDLC) in dyslipidemic patients. We evaluated the effects of new fixed-dose combinations (FDC) of fenofibrat
Autor:
Harald Schrem, Ulrich Baumann, Christian Koenecke, Lars Pape, Nikos Emmanouilidis, Frank Lehner, Alexander Kaltenborn, Hans-Friedrich Koch, Viktor Arelin, Lisa Rausch
Publikováno v:
Transplantation Research
Background Post-transplant lymphoproliferative disorder (PTLD) adversely affects patients’ long-term outcome. Methods The paired t test and McNemar’s test were applied in a retrospective 1:1 matched-pair analysis including 36 patients with PTLD a